Screening for Cancer
DELTA-P SCREENING FOR LEMS ASSOCIATED WITH SCLC
The DELTA-P (Dutch-English LEMS Tumor Association Prediction) score is a clinical tool developed in 2011 by Titulaer and colleagues—and validated in a 2020 prospective cohort study—that helps predict the risk of cancer in patients with Lambert-Eaton myasthenic syndrome (LEMS).48,51
The abbreviation is also a mnemonic that highlights the signs associated with SCLC-associated LEMS.
DELTA-P predicts SCLC with
reliability early in the course of LEMS51
*Karnofsky Performance Score is an attempt to quantify cancer patients’ general well-being and their quality of life. The score runs from 100 to 0, where 100 = perfect health and 0 = death. A cutoff value of 70 was chosen; those with values below 70 need at least occasional assistance for activities of daily living.51
Mazen Dimachkie, MD, is a leading consultant in the study of LEMS. As the Director of Neuromuscular Research at the University of Kansas Medical Center, he manages one of the busiest neuromuscular clinical trial units in North America.
NeuroseriesLive hosted a webinar featuring Dr. Dimachkie discussing LEMS: “Are My Muscles Aging? One Often-misdiagnosed Cause of Weakness and Fatigue.” Excerpts from this program appear throughout this website, and you can watch the full webinar here.†
†Sponsored by Catalyst Pharmaceuticals.
Screening Steps
A thorough patient history can help uncover key clues
Review timing of symptom onset in relation to symptom spread or exacerbation
SCLC-associated has a more rapid and aggressive onset than SCLC not associated with LEMS; this can help reveal the signs of an occult tumor52,53
Verify current or past tobacco use
The majority of cancer-related LEMS cases occur in people with a history of smoking4,13,14,43
If you suspect cancer
An X-ray, PET scan, or CT scan can reveal tumor presence4,43
Rich’s Patient History
His pursuit of a neuromuscular diagnosis yielded another discovery
Listen as Rich, a 53-year-old with LEMS, recalls the onset of symptoms that led to his eventual diagnosis of LEMS and cancer.